Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3
Prescient Therapeutics (ASX:PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with a cash balance of $14.8 million.
United States Donaldm Orourke Cell Therapy Enhancement Program Melbourne Peter Maccallum Cancer Centre Prescient Therapeutics Cell Therapy Enhancement
Source: themarketherald.com.au